VASCULAR BIOGENICS, LTD. SUPPORT AGREEMENTSupport Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of February [21], 2023, is made by and among Vascular Biogenics Ltd., an Israeli corporation (“Vibrant”), Notable Labs, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Shareholder”) of share capital (the “Shares”) of Vibrant.
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations • California
This Employment Agreement (this “Agreement”) is made and entered into this 15th day of June, 2020 (the “Effective Date”) by and between Notable Labs, Inc., a Delaware corporation (“Company”), and Joseph Wagner (“Executive”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), is entered into on September 30, 2021 (the “Effective Date”), by and between Notable Labs, Inc., a Delaware corporation with a principal place of business at 320 Hatch Drive, Foster City, CA 94404 (“Notable”) and Oncoheroes Biosciences Inc., a Delaware corporation, with a place of business at 62 Cypress St. #5, Brookline, MA 02445 (“Oncoheroes”), collectively the “Parties” and each, a “Party.”
SIDE LETTER RELATING TO PATENT ASSIGNMENT AND LICENSING AGREEMENT (“Side Letter”)Patent Assignment and Licensing Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations
This Side Letter, effective as of its date of last signature, relates to the Patent Assignment and Licensing Agreement by and between Boehringer Ingelheim International GmbH (“BII”) and Oncoheroes Biosciences Inc. (“Oncoheroes”), dated August 1, 2019, as amended by Amendment nr. 1 effective on April 5, 2020 (the “Agreement”).
CO-DEVELOPMENT AND PROFIT-SHARING AGREEMENT BETWEEN CICLOMED, LLC AND NOTABLE LABS, INC.Co-Development and Profit-Sharing Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
This Co-Development and Profit-Sharing Agreement shall become effective as of July 20, 2021 (the “Effective Date”) by and between CicloMed, LLC, a limited liability company organized under the laws of Kansas having a principal place of business at 4520 Main Street, Suite 1500, Kansas City, MO 64111 (“CicloMed”), and Notable Labs, Inc., a company incorporated under the laws of Delaware having a principal place of business at 320 Hatch Drive, Foster City, CA 94404 (“Notable”). CicloMed and Notable are individually referred to herein as a “Party” and collectively, as the “Parties.”
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into this 30th day of April, 2021 (the “Effective Date”) by and between Notable Labs, Inc., a Delaware corporation (“Company”), and Thomas Bock (“Executive”) and supersedes in all respects the Employment Agreement between Executive and the Company dated as of February 21, 2021 (the “Prior Agreement”).
LOCK-UP AGREEMENTLock-Up Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations
NOTABLE LABS, INC. SUPPORT AGREEMENTSupport Agreement • May 11th, 2023 • Vascular Biogenics Ltd. • Pharmaceutical preparations • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of February [21], 2023, is made by and among Vascular Biogenics Ltd., an Israeli corporation (“Vibrant”), Notable Labs, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of capital stock (the “Shares”) of the Company.
